The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...

Novartis announced that the FDA has granted Breakthrough Therapy designation to Scemblix® (asciminib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic ...

Novartis will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used ...

At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain. Aug 26, 2020 Human health is inextricably ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Report a suspected side effect related to Novartis product here.

Novartis aims to tackle breast cancer with bold science, collaboration, and a passion for transforming patient care. We take a bold approach to our research by including patient populations who are ...

Novartis has redesigned and scaled our response to the global refugee crisis: going beyond monetary and medicine donations to offer an innovative, inclusive and differentiated approach that is ...

At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...

Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...